CLINUVEL PHARMACEUTICALS LTD Revenue and Competitors
Estimated Revenue & Valuation
- CLINUVEL PHARMACEUTICALS LTD's estimated annual revenue is currently $13.8M per year.
- CLINUVEL PHARMACEUTICALS LTD's estimated revenue per employee is $155,000
Employee Data
- CLINUVEL PHARMACEUTICALS LTD has 89 Employees.
- CLINUVEL PHARMACEUTICALS LTD grew their employee count by 41% last year.
CLINUVEL PHARMACEUTICALS LTD's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Brand (Global) | Reveal Email/Phone |
2 | Head Global Administration | Reveal Email/Phone |
3 | Data Manager | Reveal Email/Phone |
4 | Regulatory Affairs Manager (EU) | Reveal Email/Phone |
5 | Medical Manager | Reveal Email/Phone |
6 | Pharmacovigilance Manager | Reveal Email/Phone |
7 | Logistics and Distribution Specialist | Reveal Email/Phone |
8 | Scientific Affairs | Reveal Email/Phone |
9 | Quality Assurance Associate | Reveal Email/Phone |
10 | Legal Counsel | Reveal Email/Phone |
CLINUVEL PHARMACEUTICALS LTD Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $52.4M | 338 | 28% | N/A | N/A |
#2 | $13.8M | 89 | 9% | N/A | N/A |
#3 | $18.6M | 120 | 21% | N/A | N/A |
#4 | $17.1M | 110 | -1% | N/A | N/A |
#5 | $48.1M | 310 | 6% | N/A | N/A |
#6 | $15.3M | 99 | 27% | N/A | N/A |
#7 | $13.6M | 88 | -14% | N/A | N/A |
#8 | $15.5M | 100 | 9% | N/A | N/A |
#9 | $19.7M | 127 | 8% | N/A | N/A |
#10 | $21.2M | 137 | -4% | $33.8M | N/A |
What Is CLINUVEL PHARMACEUTICALS LTD?
CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global and diversified biopharmaceutical company focused on developing and commercialising treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. As pioneers in photomedicine and understanding the interaction of light and human biology, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, DNA repair and acute or life threatening conditions. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL’s lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 and the US Food and Drug Administration in 2019 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at http://www.epp.care. Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information please go to http://www.clinuvel.com.\n\nSCENESSE® and PRÉNUMBRA® are registered trademarks of CLINUVEL PHARMACEUTICALS LTD
keywords:N/A
N/A
Total Funding
89
Number of Employees
$13.8M
Revenue (est)
41%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Melbourne
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $12.9M | 89 | 7% | N/A |
#2 | $18.7M | 89 | 7% | N/A |
#3 | $18.7M | 89 | 13% | N/A |
#4 | $12.9M | 89 | -12% | N/A |
#5 | $24.3M | 90 | 45% | N/A |